BI-HEX®-GlymaxX® cells enable efficient production of next generation biomolecules with enhanced ADCC activity

BMC Proceedings

Poster Presentation

Till Wenger¹  Anne B Tolstrup¹  Simone Schatz¹  Jochen Schaub¹  Barbara Enenkel¹  Anurag Khetan¹  Anja Puklowski¹  Jennifer Koenitzer¹  Hitto Kaufmann¹ 

[1] Boehringer-Ingelheim, 88397, Biberach an der Riss, Germany;

关键词: Transfection Efficiency;    Antibody Dependent Cellular Cytotoxicity;    Therapeutic Antibody;    CD16 Binding;    Production Cell Line;   

DOI  :  10.1186/1753-6561-7-S6-P63

来源: Springer

【 授权许可】

Unknown   
© Puklowski et al.; licensee BioMed Central Ltd. 2013. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.